The artist formerly known as financial tailor.
Joined June 2012
- Tweets 41,643
- Following 572
- Followers 3,376
- Likes 77,617
6,421 Photos and videos
Pinned Tweet
16 Jul 2018
I'm right, you're wrong, you've got a closed mind, and I don't want to talk about it.
4
2
40
Ben retweeted
Jun 12
guy who faked-it-until-he-made-it but was starting to get in over his head can’t believe his luck when llms launched
104
605
20,150
633,785
Ben retweeted
Here’s what doesn’t make any sense to me and why I don’t buy this post. If the US government believes the jailbreak allows for national security threat cyberwarfare and other such capabilities, how can they simply issue export control restrictions vs stopping the entire release?
I’ve had a number of conversations with folks inside and outside government about the current situation with Anthropic, and here is what I believe to be true:
— As we know, Anthropic publicly released its Mythos class models earlier this week under the commercial name Fable.
— Fable is Mythos with guardrails. But if those guardrails fail, then you’ve exposed Mythos and its advanced cyber capabilities to people who shouldn’t have them. (Keep in mind that Anthropic itself widely promoted the idea that Mythos was a cyberweapon and needed to be regulated as such. They asked for government regulation of Mythos and championed the guardrails on Fable. If there is a vulnerability — big or small — it is Anthropic’s responsibility to patch.)
— A highly credible trusted partner of both Anthropic and the USG who was testing Fable came forward with a jailbreak of those guardrails. The Admin asked Dario to fix the jailbreak or de-deploy the model. Dario refused.
— In their blog post, Anthropic defended its decision by saying the jailbreak isn’t serious. That is not what the trusted partner and the USG believe; nor is that kind of minimizing language consistent with Anthropic’s brand as the AI safety company. It’s difficult to fathom how they could claim a jailbreak allowing operability of a cyber weapon could be defined as not “serious.”
— In the past, Anthropic has always said that safety must be top priority and taken super seriously. In this case, Anthropic prioritized the continued offering of the consumer model over safety.
— In reaction, the Admin issued the export control. The Admin did this reluctantly. It’s been very surprised that Anthropic hasn’t wanted to cooperate with a reasonable safety request (ie fixing the jailbreak issue). Anthropic’s reaction is very much at odds with their branding and ethos as a safe AI research community.
— The Admin’s hope now is that Anthropic remediates the safety issue, the export control is lifted, and Fable goes back into general release. The Admin wants all of this to happen as soon as possible. It is frankly bewildered that Anthropic hasn’t wanted to comply with safety requests that it previously said were its highest priority.
— Those trying to misdirect and tie this action to the prior DoW/Anthropic issues are wrong. The Admin values Anthropic’s technical capabilities and feels that this issue, while serious, should be easily resolved. The ball is in Anthropic’s court.
24
6
136
31,647
20h
If Mythos is as dangerous as they say, we should probably hook it up to our nuclear arsenal before our enemies do.
1
80
Ben retweeted
Dear US government,
Since you've just blocked Fable and Mythos on critical national security grounds, here are some other tools that pose a similar threat to the American people:
- Microsoft Teams
- SAP
- Salesforce
- Jira
- Outlook
Please do what you must to save America 🇺🇸
‼️🚨 BREAKING: Amazon researchers snitched to the US government about jailbreaking Fable 5 and Mythos 5, forcing Anthropic to immediately shut down worldwide access.
A security export control directive from Commerce Secretary Howard Lutnick enforced the action.
Anthropic is fighting the directive and calls it a misunderstanding.
This isn't the first clash. The Trump administration had already tried to get Anthropic to pause the release of its latest models before this directive landed.
578
2,217
23,266
1,347,660
Jun 13
Anthropic should just buy all their top engineers citizenship with Trump's gold pass or whatever that was, seems like an easy fix. Just pay the ransom.
3
103
Jun 13
I would upgrade to a blue check, but then I'd miss out on the only place that schizophrenics are allowed to advertise.
1
52
All of these were reported over the past month:
• A new pancreatic cancer drug, daraxonrasib, that roughly doubles survival in late-stage disease
• A precision lung cancer drug, lorlatinib, that kept 55 percent of patients progression-free after 7 years, versus 3 percent on the old drug
• A prostate cancer drug, talazoparib, that halves the risk of progression
• An endometrial cancer drug, dostarlimab, where 58 percent of patients hadn't progressed after 4 years, versus 16 percent on chemo alone
• An early-detection blood test, the NHS Galleri test, that quadrupled cancer detection but missed its main goal
• An mRNA cancer vaccine that halved the risk of melanoma recurrence when added to Keytruda
• The most effective weight loss drug so far, retatrutide, which cut body weight by about 28 percent
• The first in vivo gene editing therapy, which cut hereditary angioedema attacks by 87 percent from a single injection
• A one-time gene edit, VERVE-102, that lowered LDL cholesterol by 62 percent
• A feat of pharmaceutical synthesis that raised enlicitide's manufacturing yield 14-fold using engineered enzymes
• A functional cure for hepatitis B, bepirovirsen, that cleared the virus in about 20 percent of patients
• The discovery that human cells can swap chromosome-sized DNA through nanotubes
• An ancestor of CRISPR, VIPR, found in bacteriophages, that silences genes without cutting DNA
• A preventive Covid-19 pill, ensitrelvir, that cut symptom risk by 67 percent after exposure
• The first PROTAC drug, vepdegestrant, which destroys a disease-causing protein rather than blocking it
Every month, Niko and I write a round up digging into the latest news in biotech and medicine, and this month's was astonishing.
We share some thoughts on what's responsible for this progress and what it means for science in the future.
New post!
@NikoMcCarty and I have been writing regular round ups for a little while now, but so much has happened recently that this month’s What's New in Biology post feels like it contains a year’s worth of breakthroughs.
worksinprogress.news/p/whats…
The most effective weight-loss drug so far, cancer breakthroughs, gene editing for cholesterol, ancestral CRISPR systems, a cure for some with hepatitis B, the first PROTAC drug, and more.
Read it here!
8
102
501
54,804
Ben retweeted
Jun 12
I know it’s 2026 and nuance is illegal but you can simultaneously think SpaceX rocketry is unimpressive while also thinking a $2T valuation is deep value.
3
2
16
2,067
Jun 12
I just need to subsidize demand
Jun 12
WRIGHT SAYS A GAS TAX HOLIDAY OVER THE SUMMER IS POSSIBLE TO HELP REDUCE GASOLINE PRICES
3
241
Jun 12
She walked right over it without realizing, I almost stepped on it.
2
11
903
Ben retweeted
Episode 35!
We cover the American Tobacco Company's rise to dominance, subsequent antitrust action against ATC, the Supreme Court ruling, the company's breakup, Buck Duke's diversification, philanthropy, and more!
1
3
9
3,360
Jun 11
Inflation: transitory
liquidity: ample
Oil: flowing
destiny: manifesting
euros: assimilating
singularity: approaching
84
Ben retweeted
More good news in pancreatic cancer:
Daraxonrasib recently doubled survival in metastatic disease in Phase 3. Now, combined with vopimetostat, it has shown a 92% objective response rate. This is far above the 25–35% seen with either drug alone.
Thread below 👇
6
50
241
35,098